WHO questions FDA's approval of remdesivir

Friday, 23. October 2020 18:16

World Health Organization (WHO) Chief Scientist Soumya Swaminathan (pictured) brought into question on Friday the approval of Gilead Sciences' antiviral drug Velkury (remdesivir) issued by the United States Food and Drug Administration (FDA), noting that the authorization process hasn't taken into account the solidarity study requested by the WHO.

FDA's decision was based on the data provided by Gilead, Swaminathan stressed.

The WHO study claimed that Velkury has no significant effect on COVID patients' chances to survive the disease, while Gilead criticized the trial, stressing that it is "unclear if any conclusive findings can be drawn from the study results."

Related Links: Gilead Sciences Inc.
Author:
Breaking the News / BU